InspireMD, Inc. Sustainability Profile
InspireMD, Inc., headquartered in Illinois, is a pioneering medical device company specialising in innovative solutions for the treatment of cardiovascular diseases. Founded in 2006, InspireMD has made significant strides in the industry, particularly with its proprietary MGuard™ technology, which combines a unique mesh design with a drug-eluting stent to enhance patient outcomes. With a focus on improving the safety and efficacy of vascular interventions, InspireMD operates primarily in North America and Europe, positioning itself as a leader in the interventional cardiology market. The company has achieved notable milestones, including successful clinical trials and regulatory approvals, solidifying its reputation for excellence in medical innovation. Through its commitment to advancing cardiovascular care, InspireMD continues to set itself apart with cutting-edge products that address critical patient needs.
DitchCarbon Score
How does InspireMD, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
InspireMD, Inc.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
InspireMD, Inc.'s reported carbon emissions
InspireMD, Inc., headquartered in Illinois, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that InspireMD may not yet have established a comprehensive climate strategy or may be in the early stages of developing one. As the company operates within the medical device industry, it is essential for InspireMD to consider the growing emphasis on sustainability and carbon reduction within the sector. Many organisations are increasingly adopting Science-Based Targets Initiative (SBTi) guidelines and committing to net-zero emissions, which could serve as a benchmark for InspireMD in future climate initiatives. Overall, while InspireMD has not yet disclosed specific emissions data or reduction commitments, the industry context highlights the importance of establishing a robust climate strategy to align with global sustainability goals.
How Carbon Intensive is InspireMD, Inc.'s Industry?
How Carbon Intensive is InspireMD, Inc.'s Location?
InspireMD, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
InspireMD, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Boston Scientific
Smith Plus Nephew
AngioDynamics, Inc.
B. Braun Melsungen AG
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.